ePrints

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0)

Lookup NU author(s): Dr Jingky Lozano-KuehneORCiD, Dr Nicola Cresti

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

© The Author(s) 2023.In the original version of this article, the following author (Veronica Ferguson) was omitted from the author list. Author list, Author contributions and competing interests statements have now been updated in both the PDF and HTML versions of the article.

Publication metadata

Author(s): Coombes RC, Badman PD, Lozano-Kuehne JP, Liu X, Macpherson IR, Zubairi I, Baird RD, Rosenfeld N, Garcia-Corbacho J, Cresti N, Plummer R, Armstrong A, Allerton R, Landers D, Nicholas H, McLellan L, Lim A, Mouliere F, Pardo OE, Ferguson V, Seckl MJ

Publication type: Note

Publication status: Published

Journal: Nature Communications

Year: 2023

Volume: 14

Issue: 1

Online publication date: 17/01/2023

Acceptance date: 02/04/2018

ISSN (electronic): 2041-1723

Publisher: Nature Research

URL: https://doi.org/10.1038/s41467-023-35969-4

DOI: 10.1038/s41467-023-35969-4

PubMed id: 36650166

Share